Organon opens new research facility

Organon, the human healthcare business of Akzo Nobel, has opened its new Organon Research Center USA in Cambridge, Massachusetts.

Organon's strategy in biotechnology is to develop and market biological entities that represent new therapeutic approaches within areas of interest including immunology, oncology and osteoporosis. The company will leverage its proprietary monoclonal antibody technology and is committed to partnering with academia for early research, and with biotechnology and pharmaceutical companies for product development programs and for access to the best discovery technologies. The new Cambridge research centre will be the hub of its interface with institutes and companies in the US.

'The opening of this facility is an important step in fulfilling our ambitions of expanding the breadth and depth our biotechnology research programs. We are proud to be a new member of the Cambridge research community and are thankful for the state and local support that we have received,' said Toon Wilderbeek, president of Organon International. 'We believe that expanded biotechnology research activities and collaborations are critical to fuelling our future pipeline of products to treat diseases and improve the quality of life.'

Organon and its sister businesses Diosynth Biotechnology and Intervet have a strong heritage in biotechnology. Organon's capabilities cover all aspects of drug discovery and development, from early research through clinical development and large scale manufacturing. The companies are actively involved in developing recombinant fertility treatments, recombinant vaccines and recombinant protein API's.